Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

CLX — Clorox

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 17.01%
Profit Margins 11.18%
Return on Equity 546.1%
Return on Assets 11.04%
Free Float 0.12B
Dividend Yield 5.09%
Short Int % Utilisation 8.85%

2.2 Growth

Metric Value
Revenue Growth 0.1%
Free Cash Flow 0.06B
EBITDA 12.14 (Ratio)
Enterprise Value 15.46B
EV/Revenue 2.29
EV/EBITDA 12.14

Revenue growth of 0.1% suggests mature or challenged top-line momentum.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* -5.29%
Risk / Std Dev (Ann.)* 30.45%
1-Year Price Return* -9.45%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $105.70
52-Week Range $84.70 – $128.90
Observation Count 249 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2026 FY2025
Revenue Reported revenue $6.72B $7.10B
Net income Reported net income $587.00M $810.00M
Total assets Year-end reported balance $7.79B $5.56B
Shareholders’ equity Year-end reported balance $90.00M $321.00M
Net margin Net income ÷ revenue 8.74% 11.40%
Asset turnover Revenue ÷ total assets 0.8622x 1.2775x
Equity multiplier Total assets ÷ shareholders’ equity 86.6000x 17.3240x
ROE Net margin × asset turnover × equity multiplier 652.22% 252.34%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $6.72B
Prior annual revenue $7.10B
EBIT $921.00M
Tax rate 24.02%
NOPAT = EBIT × (1 − tax rate) $699.77M
Forecast start-growth basis -5.41%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $699.77M
Add: depreciation & amortisation $247.00M
Less: capital expenditure -$207.00M
Less/(add): working-capital cash-flow movement $118.00M
Current unlevered FCFF $857.77M

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 -5.41% $661.95M $233.65M -$195.81M $111.62M $811.41M $787.78M
2 -3.43% $639.25M $225.64M -$198.23M $107.79M $774.45M $708.75M
3 -1.45% $629.96M $222.36M -$204.35M $106.23M $754.20M $650.61M
4 0.52% $633.26M $223.52M -$214.47M $106.78M $749.10M $609.13M
5 2.50% $649.09M $229.11M -$229.11M $109.45M $758.55M $581.42M

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 0.54
Cost of equity 7.69%
Pre-tax cost of debt 3.10%
WACC 6.09%
WACC validation requires assumption review

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $21.67B
Implied terminal EV / EBITDA 20.00x
Terminal value as % of enterprise value 82.85%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $3.34B
Present value of terminal value $16.13B
Indicated enterprise value $19.47B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $19.47B
Less: gross interest-bearing debt $5.52B
Add: cash and equivalents $143.00M
Add: affiliate investments $0.00
Less: minority interests $162.00M
Indicated common equity value $13.93B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 122,132,000.00
Share-count basis reported diluted weighted-average shares
Current market price $106.59
DCF indicative value per share $114.03
Indicative value vs. market price 6.98%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range review required
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% within review band

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 3/4 evidenced checks
Lynch-inspired balance-and-growth checks 3/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:27:05.507506 UTC; latest reported fiscal period: 2026-06-30 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -26.59% -3.33%
Adjusted R² 0.05 0.21
Annualised residual volatility 28.84% 26.12%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.03 (0.19) 0.62 (3.50)
Size (SMB) 0.74 (3.23) 0.77 (3.43)
Value (HML) 0.13 (0.64) -0.46 (-2.07)
Profitability (RMW) NM 1.02 (5.46)
Investment (CMA) NM 0.89 (2.75)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequityclxconsumer-stapleshousehold-productsnasdaq